| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 19,251 | 17,615 | 17,063 | NaN |
| Purchases of inventory | 2,778 | 2,496 | 2,668 | NaN |
| Other cost of sales | 745 | 808 | 519 | NaN |
| Gross profit | 15,728 | 14,311 | 13,876 | NaN |
| Sales and marketing | 12,841 | 11,938 | 12,053 | NaN |
| General and administrative | 6,061 | 7,090 | 7,226 | NaN |
| Research and development | 5,629 | 5,691 | 3,748 | NaN |
| Total operating expenses | 24,531 | 24,719 | 23,027 | NaN |
| Operating loss | -8,803 | -10,408 | -9,151 | NaN |
| Interest expense | 1,424 | 1,250 | 1,269 | NaN |
| Other expense, net | -395 | 20 | -2,751 | NaN |
| Loss before income taxes | -10,622 | -11,638 | -13,171 | NaN |
| Income tax benefit (expense) | -11 | -17 | 16 | NaN |
| Net loss | -10,611 | -11,621 | -13,187 | -23,779 |
| Fair value of common stock issued related to loan amendment | NaN | 0 | 2,152 | NaN |
| Debt issuance costs | 319 | NaN | NaN | NaN |
| Change in fair value of loan facility | -198 | 555 | 922 | -155 |
| Change in fair value of warrant liabilities | 625 | -617 | -40 | -1,532 |
| Depreciation and amortization | 627 | 700 | 574 | 1,073 |
| Stock-based compensation | 1,101 | 1,373 | 2,777 | 5,369 |
| Non-cash lease expense | 233 | 228 | 224 | 438 |
| Loss on fixed asset disposal | -53 | -5 | -247 | -343 |
| Loss on patent disposal | 2 | 0 | 5 | 6 |
| Remeasurement and foreign currency transaction loss | -9 | 0 | -17 | NaN |
| Excess and obsolete inventory related charges | -57 | -115 | -152 | -543 |
| Provision for credit losses | 0 | 7 | -11 | -6 |
| Amortization of premium of marketable securities | -77 | -84 | -31 | -193 |
| Non-cash changes in the fair value of nqdc plan | -19 | 134 | -28 | 1,097 |
| Trade and other receivables | -799 | -81 | 2,341 | 1,373 |
| Prepaids and other current assets | 90 | -509 | 118 | -375 |
| Inventory | -752 | -198 | -144 | 810 |
| Operating lease liability | -154 | -189 | -249 | -467 |
| Corporate-owned life insurance ('coli') asset | 0 | 0 | 0 | -406 |
| Other long-term assets | -77 | -464 | 235 | 294 |
| Accounts payable and accrued expenses | -1,786 | 983 | 861 | 901 |
| Accrued wages and fringe benefits | 57 | 2,018 | -2,146 | -2,510 |
| Current non-qualified deferred compensation liability | 262 | -63 | -30 | -1,709 |
| Other current liabilities | -481 | 30 | 292 | -403 |
| Non-qualified deferred compensation plan liability | -61 | 174 | 100 | 1,607 |
| Contract liabilities | -8 | -8 | -8 | -17 |
| Net cash used in operating activities | -10,072 | -5,438 | -5,219 | -20,538 |
| Purchase of marketable securities | 3,937 | 1,963 | 7,886 | 3,460 |
| Maturities of marketable securities | 6,000 | 2,000 | 3,500 | 22,000 |
| Purchase of plant and equipment | 19 | -674 | 934 | 745 |
| Capitalized software development costs | NaN | 635 | NaN | NaN |
| Patent filing fees | 3 | 65 | 21 | 13 |
| Net cash provided by investing activities | 2,041 | 11 | -5,341 | 17,782 |
| Proceeds from private placement of common stock | NaN | 0 | 14,792 | NaN |
| Proceeds from loan facility, net of issuance costs | 49,081 | NaN | NaN | NaN |
| Issuance costs associated with private placement | NaN | 0 | 1,058 | NaN |
| Repayment of previous credit agreement | 42,984 | NaN | NaN | NaN |
| Proceeds from exercise of stock options | 0 | 1 | 32 | 374 |
| Employee stock purchase plan ('espp') purchases | NaN | 247 | 0 | 548 |
| Net cash provided by financing activities | 6,097 | 248 | 13,766 | 922 |
| Net increase/(decrease) in cash and cash equivalents | -1,934 | -5,179 | 3,206 | -1,834 |
| Cash and cash equivalents beginning of the period | 10,243 | 15,422 | 14,050 | NaN |
| Cash and cash equivalents end of the period | 8,309 | 10,243 | 15,422 | NaN |
AVITA Medical, Inc. (RCEL)
AVITA Medical, Inc. (RCEL)